ArticleBioinformatics (Oxford, England)2026
De novo epitope-specific antibody design via time-dependent guidance.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
motivationDe novo antibody design requires jointly determining the global binding orientation and shaping flexible CDR loops to engage a target epitope. Diffusion-based approaches such as RFantibody are capable of this joint task but frequently produce severe steric clashes requiring extensive post-hoc filtering. Flow-based methods such as IgFlow and FlowDesign offer more stable generation but remain restricted to pre-aligned frames, precluding true de novo design. Achieving structural integrity and epitope specificity simultaneously in this setting remains an open challenge.
resultsWe propose TiDE-Ab, a conditional SE(3) flow matching framework for de novo epitope-specific antibody design. By conditioning on unpaired antigen and antibody structures without any pre-aligned frame, TiDE-Ab inherits the structural stability of flow matching while enabling global binding pose search from scratch. To further improve epitope targeting, we introduce Time-Dependent Classifier-Free Guidance (TD-CFG), which replaces static conditioning with an adaptive schedule: strong guidance early to establish the global binding pose, followed by gradual relaxation for precise local CDR refinement. On 55 non-redundant benchmark complexes, TiDE-Ab outperforms RFantibody with higher epitope recall (0.935 vs. 0.878) and over 95% fewer steric clashes. In therapeutic case studies on TGF-β and IL-17A, TiDE-Ab reproduced the binding profiles of clinical antibodies across isoform-selective and cross-reactive epitopes, whereas RFantibody consistently failed to produce viable candidates. AVAILABILITY: Source code, data, and trained models are available at https://github.com/SNU-CSSB/TiDE-Ab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.